
Please try another search
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Name | Age | Since | Title |
---|---|---|---|
Colin Michael Bond | 65 | 2025 | Non-Executive Independent Director |
Arun Kumar Pillai | 64 | 2021 | Founder & Non-Executive Director |
P. N. Rangarajan | - | - | Member of Scientific Advisory Board |
Vijay Paul Karwal | 54 | 2025 | Non-Executive Independent Director |
Raghavan Varadarajan | - | - | Member of Scientific Advisory Board |
Bharat Dhirajlal Shah | 78 | 2024 | Non-Executive Non-Independent Director |
Debarati Sen | 57 | 2025 | Non-Executive Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review